Gastrointestinal Dysfunction and Levodopa Therapeutic Response in Parkinson’s Disease: A Brazilian Cross-sectional Study
Objective: To investigate the relation between constipation and the onset time of levodopa therapeutic effect in Parkinson's disease (PD). Background: Levodopa therapeutic response depends on…Clinical Picture of Acute Akinetic Collapse Leading to Multi-Day Immobility in Parkinson’s Disease
Objective: To investigate the clinical characteristics of Parkinson's disease (PD) patients who experienced acute akinesia and immobilization requiring emergency medical care. Background: PD patients sometimes…Unraveling the Variability in Amantadine Response for Levodopa-Induced Dyskinesias: The Impact of Clinical and Genetic Factors
Objective: To identify demographic, clinical, and genetic factors associated with the outcomes of amantadine treatment in dyskinetic Parkinson’s disease (PD) patients. Background: While recent advancements…Updated Meta-analysis Assessing GLP-1 Agonists for Parkinson’s Disease
Objective: Evaluate the efficacy and safety of Glucagon-like peptide-1 (GLP-1) agonists on Parkinson’s disease (PD). Background: The idea of repositioning drugs used to treat PD…Organoid-Based AI Clinical Trial Platform for Phase 0 Studies in Parkinson’s Disease
Objective: we developed an organoid-based AI-driven platform to classify patient specific molecular subtypes and predict drug efficacy through an AI-powered validation pipeline. Patient-derived induced pluripotent…Lysosomal Lipid Dysregulation in Parkinson’s Disease: Genetic and Medication Effects in CSF Metabolomics
Objective: Define lipid signatures in sporadic, LRRK2, and GBA1 PD and pre-manifest carriers and assess medication impacts. Background: Lysosomal dysfunction contributes to PD, particularly in…Biomarker Panels for Parkinson’s Disease using Multi-Omics Approach: Recent Developments and Future Directions
Objective: The main objective is to identify potential biomarker panels that may represent disease onset, progression, and risk factors for Parkinson's disease (PD). Background: PD…Sex Differences in α-Synuclein Seed Amplification Assay Parameters and Longitudinal Clinical Subtypes of Parkinson’s Disease
Objective: To investigate differences in baseline α-synuclein seed amplification assay (SAA) metrics and longitudinal clinical subtypes of Parkinson’s disease (PD) between the two biological sexes.…AntiSaccadeNet: A Deep Learning Framework for Differentiating Parkinsonian Disorders through Antisaccade Time Series Classification
Objective: To develop and evaluate a deep learning architecture (AntiSaccadeNet) that utilizes continuous antisaccade eye movement time-series data to differentiate between Parkinson's disease (PD) and…Sleep-wake modulation of subthalamic activity in patients with Parkinson’s disease and conventional or adaptive deep brain stimulation
Objective: To describe the activity of the subthalamic nucleus (STN) during wake and sleep in patients with Parkinson’s disease (PD) with conventional (cDBS) or adaptive…
- « Previous Page
- 1
- …
- 163
- 164
- 165
- 166
- 167
- …
- 181
- Next Page »